Loading...
•
Mar 31, 2020
Replimune Q4 2020 Earnings Report
Reported financial results for the fiscal fourth quarter and year ended March 31, 2020, and provided a business update.
Key Takeaways
Replimune Group, Inc. announced its financial results for the fiscal fourth quarter and year ended March 31, 2020. The company is focused on developing oncolytic immuno-gene therapies and plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).
Continued progress developing pipeline of oncolytic immuno-gene therapies.
Released additional data with RP1 in lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD1 refractory cutaneous melanoma.
Announced plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).
Established clinical proof of principle with RP1 in immune-responsive tumor types.
Replimune
Replimune
Forward Guidance
Replimune believes that its existing cash and cash equivalents and short-term investments along with its debt commitments will enable it to fund its operating expenses and capital expenditure requirements through 2022.